HEART AND LUNG THERAPIES
Xenios AG – a Fresenius Medical Care company – is a pioneer in extracorporeal heart & lung support.
Our dedication to improve patients’ lives, drives us to constantly develop high-quality products and application-related service excellence, which allow to replace standard therapies with superior extracorporeal solutions.
On that account Xenios stands for a change of paradigm in intensive-care medicine and forms a significant part of FME’s holistic multi-organ approach.
THE XENIOS CONSOLE
Dedicated technology combines both heart and lung support in one single platform – a platform that is universally usable, individual and compatible with applications of our parent company, Fresenius Medical Care.
Novalung therapy allows to mitigate, prevent or replace mechanical ventilation by extracorporeal gas exchange. It enables caregivers to give the lung time to heal and change the therapy environment in the ICU – from CO2 removal to full oxygenation.
Medos is your partner experienced in cardiopulmonary solutions for more than 30 years: highly skilled employees and high-quality manufacturing, for the benefit of cardiac surgeons, perfusionists and patients.
Our internationally acclaimed clinical support team accompanies the clinical application of all Xenios products. Our specialists trained in intensive care are available on a telephone hotline. The clinical support team also provides support on-site in hospitals during initial applications of Novalung products and offers customized training courses.
LEARNING WITH XENIOS
LOOKING FOR FURTHER THERAPY- AND XENIOS PRODUCT INFORMATION?
Join our Xenios Campus to explore various eLearnings for example expert interviews, best-practice-cases, medical knowledge, hands-on-tutorials, priming instructions and more. Of course, free of charge and without obligation.
ESICM congress LIVES 2019, Berlin
ESICM’s annual congress, LIVES, attracts audiences of over 6,000 physicians, anaesthetists, trainees and nursing and allied health professionals, every year, from every continent and 97 different countries. Xenios - a Fresenius Medical Care company, was part of the Society’s 32nd annual congress at the CityCube, Berlin from 28 September – ...
ERS 2019, Madrid
The annual ERS Congress is a showcase of excellence across the entire field of respiratory Medicine. ERS International Congress 2019 was hosted in Madrid, Spain from 28 September to 2 October 2019 at IFEMA. This year, the Congress gathered more than 20,000 delegates over five days to witness more than ...
Merger: Novalung becomes fully integrated within Xenios
Novalung GmbH, which specialises in solutions for respiratory failure, was absorbed into Xenios AG on 30 August 2019. Processes will be streamlined as a result and the company will become more closely aligned with the parent company Fresenius Medical Care. Novalung was established in 2003 and specialises in the treatment ...
28. September – 02. October
ESICM Lives 2019
ESICM Lives 2019 - European Society Of Intensive Care Medicine - Berlin, Germany